Sodium-glucose cotransporter 2 inhibition, uric acid, and heart failure: correlation without causation?
作者信息
Carter Spencer, Hendren Nicholas S, Grodin Justin L
机构信息
Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
出版信息
Eur J Heart Fail. 2022 Jun;24(6):1077-1079. doi: 10.1002/ejhf.2516. Epub 2022 May 9.
PMID:35485178
Abstract
摘要
相似文献
1
Sodium-glucose cotransporter 2 inhibition, uric acid, and heart failure: correlation without causation?
Eur J Heart Fail. 2022 Jun;24(6):1077-1079. doi: 10.1002/ejhf.2516. Epub 2022 May 9.
2
Sodium-glucose cotransporter 2 inhibitor treatment lowers serum uric acid in patients with heart failure with reduced ejection fraction - lessons from clinical trials. Letter regarding the article 'Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF'.钠-葡萄糖协同转运蛋白2抑制剂治疗可降低射血分数降低的心力衰竭患者的血清尿酸水平——来自临床试验的经验教训。关于文章《达格列净降低尿酸浓度，尿酸是DAPA-HF中不良结局的独立预测因子》的信函
Eur J Heart Fail. 2022 Oct;24(10):1993-1994. doi: 10.1002/ejhf.2666. Epub 2022 Sep 9.
3
Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus.心力衰竭风险分层与钠-葡萄糖共转运蛋白 2 抑制剂在 2 型糖尿病患者中的疗效。
Circulation. 2019 Nov 5;140(19):1569-1577. doi: 10.1161/CIRCULATIONAHA.119.042685. Epub 2019 Aug 31.
4
Advancing the fight against fibrosis in patients with heart failure: The contribution of sodium-glucose cotransporter 2 inhibition.推进心力衰竭患者抗纤维化治疗：钠-葡萄糖协同转运蛋白2抑制剂的作用
Eur J Heart Fail. 2024 Feb;26(2):285-287. doi: 10.1002/ejhf.3125. Epub 2024 Jan 9.
5
Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis.2型糖尿病患者中钠-葡萄糖协同转运蛋白2抑制与心血管风险降低：利钠作用的新角色
Kidney Int. 2016 Mar;89(3):524-6. doi: 10.1016/j.kint.2015.12.038.
6
Factors associated with the uric acid-lowering effects of sodium-glucose cotransporter-2 inhibition in patients with type 2 diabetes: Insights from the randomized PROTECT trial.2型糖尿病患者中与钠-葡萄糖协同转运蛋白2抑制作用降尿酸效果相关的因素：来自随机PROTECT试验的见解
Diabetes Obes Metab. 2024 Mar;26(3):1110-1113. doi: 10.1111/dom.15368. Epub 2023 Nov 14.
7
Sodium-glucose cotransporter 2 inhibitors in frail, older people with type 2 diabetes and heart failure: do we have enough evidence to confidently support the use?钠-葡萄糖协同转运蛋白2抑制剂在体弱的老年2型糖尿病合并心力衰竭患者中的应用：我们是否有足够的证据来有力支持其使用？
Expert Rev Clin Pharmacol. 2023 Jul-Dec;16(9):771-774. doi: 10.1080/17512433.2023.2247977. Epub 2023 Aug 18.
8
Reconceptualization of the Molecular Mechanism by Which Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Events.钠-葡萄糖协同转运蛋白2抑制剂降低心力衰竭事件风险的分子机制的重新概念化
Circulation. 2019 Aug 6;140(6):443-445. doi: 10.1161/CIRCULATIONAHA.119.040909. Epub 2019 Aug 5.
9
Sodium-glucose cotransporter-2 inhibitors in type 2 diabetes: a magic potion to reduce heart failure?2型糖尿病中的钠-葡萄糖协同转运蛋白2抑制剂：一种降低心力衰竭的神奇药物？
Expert Rev Clin Pharmacol. 2019 Aug;12(8):693-695. doi: 10.1080/17512433.2019.1635453. Epub 2019 Jun 30.
10
Sodium-glucose cotransporter 2 inhibitors on top of intravenous iron in patients with heart failure and iron deficiency: Any incremental effect?心力衰竭合并缺铁患者在静脉补铁基础上加用钠-葡萄糖协同转运蛋白2抑制剂：有额外效果吗？
Eur J Heart Fail. 2023 Dec;25(12):2199-2201. doi: 10.1002/ejhf.3064. Epub 2023 Oct 31.
引用本文的文献
1
The association between gout and subsequent cardiovascular events: a retrospective cohort study with 132,000 using propensity score matching in primary care outpatients in Germany.痛风与后续心血管事件之间的关联：一项在德国初级保健门诊患者中使用倾向评分匹配法对132,000例患者进行的回顾性队列研究。
Clin Res Cardiol. 2024 Sep 10. doi: 10.1007/s00392-024-02537-9.
Zotero 插件